Advertisement
Screener

Citius Oncology, Inc. (CTOR) Graph

CTOR Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2021-03-31: Net income -$9.39K.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

CTOR revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$1.49MCost of revenue$491.84KGross profit$1.00MOperating expenses$9.72MOperating income-$8.72MResearch & development$218.50KPre-tax income-$9.03MIncome tax-$107.35KNet income-$8.92M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 1 month

Period endNet income
2021-03-31-$9.39K

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$1.49M$491.84K$218.50K$9.72M-$107.35K-$8.92M
2026-03-31$1.67M$328.88K$1.08M$29.95M-$231.21K-$26.61M
2025-12-31$3.94M$789.21K$1.02M$8.41M$264.24K-$5.53M
2025-06-30(m)(m)$938.28K$4.94M$264.24K-$5.37M
2025-03-31(m)(m)$3.14M$7.47M$264.24K-$7.74M
2024-12-31(m)(m)$1.26M$6.39M$264.24K-$6.66M
2024-06-30(m)(m)$1.13M$4.63M$144.00K-$4.77M
2024-03-31(m)(m)$1.35M$4.69M$144.00K-$4.84M
2023-12-31(m)(m)$1.15M$4.58M$144.00K-$4.73M
2023-09-30(m)(m)(m)(m)(m)$157.94K
2023-06-30(m)(m)(m)(m)(m)$616.30K
2023-03-31(m)(m)(m)(m)(m)$611.73K
2021-06-30(m)(m)(m)(m)(m)-$724.00

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-03-31$5.61M$1.12M$2.10M$38.36M$33.03K-$32.14M
2025-03-31(m)(m)$4.40M$13.87M$528.48K-$14.39M
2024-06-30(m)(m)(m)(m)(m)$742.29K
2024-03-31(m)(m)$2.50M$9.27M$288.00K-$9.56M
2023-06-30(m)(m)(m)(m)(m)$1.23M

Revenue and expense 7 month

Period endNet income
2021-09-30-$10.11K

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$7.11M$1.61M$2.32M$48.08M-$74.32K-$41.07M
2025-06-30(m)(m)$5.34M$18.81M$792.72K-$19.76M
2024-06-30(m)(m)$3.63M$13.90M$432.00K-$14.34M
2023-09-30(m)(m)(m)(m)(m)$1.39M

Revenue and expense 10 month

Period endNet income
2021-12-31-$10.11K

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-09-30$6.42M$23.52M$1.06M-$24.76M
2024-09-30$4.93M$20.57M$576.00K-$21.15M
2023-12-31(m)(m)(m)$2.42M
2023-09-30$4.24M$12.12M$576.00K-$12.70M
2022-12-31(m)(m)(m)$380.81K

Similar stocks

Stock NameCountryMarket CapPE Ratio
Anixa Biosciences Inc (ANIX)United States$0.096B
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
ProMIS Neurosciences Inc. (PMN)$0.102B
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
Rallybio Corp (RLYB)United States$0.089B
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
Equillium, Inc. (EQ)United States$0.109B-11.27